Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer
•
Dermatology
•
Oncology
What criteria are used to select patients who have locally advanced BCC patients for treatment with sonidegib?
What treatment combinations be used to maximize results?
Related Questions
Are there certain patient characteristics that drive you to recommend intralesional 5-FU or MTX for a large SCC on the back?
What factors do you weigh most heavily in the selection of radiotherapy versus topical treatments for lentigo maligna in a patient who is not a surgical candidate?
After achieving clinical response to bexarotene for cutaneous lymphoma (e.g., MF stage Ib or FMF), do you wean to the lowest dose for sustained remission, and if so, when?
Have you considered intralesional cempilumab for locally advanced NMSC/KCs prior to surgery?
What biologics would you use in a patient with rheumatoid arthritis who developed multiple basal cell carcinomas requiring Mohs surgery while on a TNF-inhibitor and did not respond to rituximab?
Have you used itraconazole as a primary or adjunct therapy for individuals with numerous BCCs?
Would you consider proceeding with a sentinel lymph node biopsy after wide excision revealed 1.2 mm residual non-ulcerated T2a melanoma on the upper back?
In what clinical scenarios do you consider pre- or post-treatment with Imiquimod for cutaneous melanoma?
Do you obtain MRI for cutaneous SCC with microscopic PNI to assess for gross perineural tumor spread?
Is there a general consensus on margins to use when treating SCCIS or BCC with ED&C?